Actionable activating oncogenic ERRB2/HER2 transmembrane and juxtamembrane domain mutations

Deregulated HER2 is a target of many approved cancer drugs. We analyzed 111,176 patient tumors and identified recurrent HER2 transmembrane domain (TMD) and juxtamembrane domain (JMD) mutations, including G660D, R678Q, E693K and Q709L. Using a saturation mutagenesis screen and testing of patient-deri...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Cancer Cell
Main Authors: Pahuja, Kanika Bajaj, Nguyen, Thong T., Jaiswal, Bijay S., Prabhash, Kumar, Thaker, Tarjani M., Senger, Kate, Chaudhuri, Subhra, Kljavin, Noelyn M., Antony, Aju, Phalke, Sameer, Kumar, Prasanna, Mravic, Marco, Stawiski, Eric W., Vargas, Derek, Durinck, Steffen, Gupta, Ravi, Khanna-Gupta, Arati, Trabucco, Sally E., Sokol, Ethan S., Hartmaier, Ryan J., Singh, Ashish, Chougule, Anuradha, Trivedi, Vaishakhi, Dutt, Amit, Patil, Vijay, Joshi, Amit, Noronha, Vanita, Ziai, James, Banavali, Sripad D, Ramprasad, Vedam, DeGrado, William F., Bueno, Raphael, Jura, Natalia, Seshagiri, Somasekar
Formato: Artigo
Idioma:Inglês
Publicado em: 2018
Assuntos:
Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC6248889/
https://ncbi.nlm.nih.gov/pubmed/30449325
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.ccell.2018.09.010
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados